Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Open accessThe DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index; 128 of the 188 sources its claims cite were checked for support.
Abstract
The advent of induced pluripotent stem cells (iPSCs) has advanced our understanding of the molecular mechanisms of human disease, drug discovery, and regenerative medicine. As such, the use of iPSCs in drug development and validation has shown a sharp increase in the past 15 years. Furthermore, many labs have been successful in reproducing many disease phenotypes, often difficult or impossible to capture, in commonly used cell lines or animal models. However, there still remain limitations such as the variability between iPSC lines as well as their maturity. Here, we aim to discuss the strategies in generating iPSC-derived cardiomyocytes and neurons for use in disease modeling, drug development and their use in cell therapy.
Overview
CoChat Summary
TL;DR
This review discusses how induced pluripotent stem cell (iPSC)-derived cardiomyocytes, neurons, and organoids are used for disease modeling, drug discovery, and cell therapy, with emphasis on cardiovascular and neurological applications. It also covers remaining hurdles including iPSC line variability, cell immaturity, and immune rejection in transplantation.
Key findings
- iPSC-derived cardiomyocytes recapitulate cardiac channelopathies and cardiomyopathies and have enabled drug discovery: e.g., nicorandil and PD118057 shortened action potentials in type-2 LQTS cells, mexiletine analogues enhanced INa potency/selectivity for type-3 LQTS, and verapamil showed the strongest inhibition of contractile function among four calcium channel blockers tested in HCM cells.
- iPSC-derived neurons model AD, PD, ALS, ASD, and SMA; examples include docosahexaenoic acid alleviating stress responses in AD neurons, Coenzyme Q10/rapamycin/GW5074 in LRRK2- and PINK1-mutant PD cells, ropinirole in TDP-43/FUS ALS motor neurons, and IGF-1 or hyperforin rescuing TRPC6-mutant ASD neuronal abnormalities.
- Organoid platforms support screening: >10,000 cardiac organoids were screened to identify optimal maturation conditions; >1000 FDA-approved drugs were screened in hPSC-forebrain organoids, identifying hippeastrine hydrobromide against ZIKV; a 50,000-compound screen in fragile X neuronal progenitors identified compounds inducing FMRP expression.
- HLA-homozygous iPSC banking can cover large populations from few donors: 55 donors for ~80% of the Japanese population, 150 iPSC lines for ~93% of the UK, 140 lines for ~90% of Japan, and ~80 lines for 50% coverage in California; CiRA's three clinical-grade lines cover 32% of Japan, Korea's 10 lines cover 41%, and Taiwan's 13 lines cover ~16% of Taiwanese.
Methods
- Narrative review (no primary data collection) covering iPSC generation and differentiation into cardiomyocytes, neurons, and organoids for disease modeling, drug discovery, and cell therapy.
- Synthesizes published preclinical and clinical studies, including high-throughput screening studies, HLA banking calculations, and CRISPR/Cas9 genome-editing approaches.
- Includes a table (Table 1) outlining iPSC-based clinical trials current as of 2021.
Limitations
- Stated by the paper: iPSC-derived cells are immature and lack intercellular communication, making complex adult disease mimicry difficult; many diseases are polygenic/heterogeneous (e.g., ASD) so a single patient line may not yield a single hit compound; reprogramming and differentiation protocol reproducibility is a recurring issue; 5–46% of phenotypic variability in iPSCs stems from normal human genetic variation (inter- and intraclone); high-throughput miniaturization challenges include low cell numbers, media evaporation, and low-volume dispensing accuracy; organoids represent fetal-like rather than adult structures; CRISPR/Cas9 off-target cleavage risks oncogenic mutations; HLA-edited cells carry increased tumorigenicity risk; autologous transplantation is time-consuming and expensive.
- Evident from the text: the review is descriptive and does not present new experimental data; several cited clinical trials (e.g., Help Therapeutics Phase 1/2, Cuorips/Osaka Phase 1) lacked efficacy data at the time of writing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
87 Valid · 19 Not valid · 34 Not checked · 39 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Using iPSC-derived cardiomyocytes from type-3 LQTS patients with SCN5A mutation revealed abnormal calcium transients with diminished INa current density [11].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 2. Drug Discovery Using iPSC-Derived Disease Models > 2.1. Cardiomyocytes
What the sources say
- Disputedcites [11] Hong L. Zhang M. Ly O.T. Chen H. Sridhar A. Lambers E. Chalazan B. Youn S.-W. Maienschein-Cline M. Feferman L. Human induced pluripotent stem cell-derived atrial cardiomyocytes carrying an SCN5A mutation identify nitric oxide signaling as a mediator of atrial fibrillation Stem Cell Rep. 2021 16 1542 1554 10.1016/j.stemcr.2021.04.019 34019817 PMC8190590 sourceExperimental — accuracy not yet measured
The Results section on AF iPSC-aCMs reports abnormal calcium transients in SCN5A-mutant atrial cardiomyocytes, but these were studied in an atrial-fibrillation model, not cells from type-3 LQTS patients. The same section reports no significant change in sodium-current amplitude and a marked increase in late sodium current (INa,L), contrary to the claimed diminished INa current density. Page numbers are unavailable in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The capacity of iPSCs for the scalable production of diverse cell types benefits researchers by reducing obstacles with procedures such as apheresis, which involves separating specific components from the blood and retuning the remaining components to the donor’s circulation, whilst obtaining human cells [3].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 1. Introduction
What the sources say
- Partly supportedcites [3] Carvajal-Vergara X. Sevilla A. D’Souza S.L. Ang Y.S. Schaniel C. Lee D.F. Yang L. Kaplan A.D. Adler E.D. Rozov R. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome Nature 2010 465 808 812 10.1038/nature09005 20535210 PMC2885001 sourceExperimental — accuracy not yet measured
The paper reports that patient-derived iPSCs differentiated into multiple cell types and describes iPSC-derived cells as a resource for studying disease (Abstract; page unavailable). It does not establish scalable production or say that iPSCs reduce obstacles associated with apheresis; its patient cells were obtained from skin biopsies (Methods Summary, Cell culture; page unavailable). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Various cell models built with iPSC derivatives have been shown to resemble in vivo or primary cell counterparts at transcriptional, cellular, and functional levels whilst leaving little interference to the genetic content [4,5,6,7].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 1. Introduction
What the sources say
- Partly supportedcites [4] Caspi O. Huber I. Gepstein A. Arbel G. Maizels L. Boulos M. Gepstein L. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells Circ. Cardiovasc. Genet. 2013 6 557 568 10.1161/CIRCGENETICS.113.000188 24200905 sourceExperimental — accuracy not yet measured
The Generation of the ARVC Patient-Specific hiPSCs section reports that the cells retained the patient’s PKP2 mutation and had a normal karyotype. CM Differentiation reports cardiac gene expression, cell markers, and electrical activity; the Discussion says the derived cells reproduced key ARVC pathology. These findings support resemblance in this disease model, but the paper does not establish that producing iPSC-derived models causes little interference with genetic content generally. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [5] Moretti A. Bellin M. Welling A. Jung C.B. Lam J.T. Bott-Flügel L. Dorn T. Goedel A. Höhnke C. Hofmann F. Patient-specific induced pluripotent stem-cell models for long-QT syndrome N. Engl. J. Med. 2010 363 1397 1409 10.1056/NEJMoa0908679 20660394 source
- Not checked — no full text of the sourcecites [6] Egashira T. Yuasa S. Suzuki T. Aizawa Y. Yamakawa H. Matsuhashi T. Ohno Y. Tohyama S. Okata S. Seki T. Disease characterization using LQTS-specific induced pluripotent stem cells Cardiovasc. Res. 2012 95 419 429 10.1093/cvr/cvs206 22739119 source
- Not checked — no full text of the sourcecites [7] Itzhaki I. Maizels L. Huber I. Zwi-Dantsis L. Caspi O. Winterstern A. Feldman O. Gepstein A. Arbel G. Hammerman H. Modelling the long QT syndrome with induced pluripotent stem cells Nature 2011 471 225 229 10.1038/nature09747 21240260 source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Even though rigorous testing is undertaken during the development stages, 90% of drugs fail clinical trials [2].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 1. Introduction
What the sources say
- Could not verifycites [2] Li S. Pan H. Tan C. Sun Y. Song Y. Zhang X. Yang W. Wang X. Li D. Dai Y. Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient iPSC-Derived Cardiomyocytes with MT-RNR2 Mutation Stem Cell Rep. 2018 10 808 821 10.1016/j.stemcr.2018.01.013 PMC5918198 29456182 sourceExperimental — accuracy not yet measured
The Introduction discusses the difficulty of obtaining patient cardiomyocytes, and the Experimental Procedures describe cell-based experiments; neither addresses clinical-trial outcomes. Searches for the 90% figure and for drug-development failure rates found no supporting passage in our copy. (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The physiological and genetic differences between human and animals leads to potential differences in terms of function, mechanisms, and signaling pathways [14,15].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 2. Drug Discovery Using iPSC-Derived Disease Models
What the sources say
- Partly supportedcites [14] Lan F. Lee A.S. Liang P. Sanchez-Freire V. Nguyen P.K. Wang L. Han L. Yen M. Wang Y. Sun N. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells Cell Stem Cell 2013 12 101 113 10.1016/j.stem.2012.10.010 23290139 PMC3638033 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) explains that human and mouse hearts predominantly use different myosin isoforms and that the same HCM mutation can have different functional consequences in those isoforms. This supports the claim about potential functional differences, but the paper does not establish a general human–animal difference in mechanisms or signaling pathways. (LLM, conf=0.86)
- Partly supportedcites [15] Han L. Li Y. Tchao J. Kaplan A.D. Lin B. Li Y. Mich-Basso J. Lis A. Hassan N. London B. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells Cardiovasc. Res. 2014 104 258 269 10.1093/cvr/cvu205 25209314 PMC4217687 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that mouse models cannot represent the genetic diversity of human hypertrophic cardiomyopathy and that patient-specific disease mechanisms need study. It does not establish that physiological differences between humans and animals cause differences in function or signaling pathways. (LLM, conf=0.82)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
100 more claims · 53 with their cited sources checked
Create a free account to see all 179 claims and every source verdict.
- It may state two separate claims as one. 54
- Probably not a substantial claim. 27
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 3. iPSC-Based Cell Therapy > 3.1. HLA-Homozygous iPSC Banking
“This was confirmed in mice showing that iPSC-derived cell implantation leads to cellular apoptosis and T cell proliferation [94].”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > References
“94. Guha P. Morgan J.W. Mostoslavsky G. Rodrigues N.P. Boyd A.S. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells Cell Stem Cell 2013 12 407 412”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 2. Drug Discovery Using iPSC-Derived Disease Models > 2.2. Neurons
“Ohuchi et al., 2006, first used SMA patient iPSC-derived motor neurons and astrocytes”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > References
“51. Ohuchi K. Funato M. Kato Z. Seki J. Kawase C. Tamai Y. Ono Y. Nagahara Y. Noda Y. Kameyama T. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog Stem Cells Transl. Med. 2016 5 152 163”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > 3. iPSC-Based Cell Therapy
“Other notable Phase 1 clinical trials in Japan includes an iPSC-derived cardiomyocyte sheet from a group comprising Cuorips Inc. and Osaka University [90]; their preclinical studies on ischemic cardiomyopathy pig models have shown improved cardiac function”
§ Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy > References
“90. Doi D. Magotani H. Kikuchi T. Ikeda M. Hiramatsu S. Yoshida K. Amano N. Nomura M. Umekage M. Morizane A. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s disease Nat. Commun. 2020 11 3369”
Citations
Cites
Cerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372 · cited 1×
“These 3D “organoids” are often found to have instructive morphogenetic cues resulting in self organization similarly found in vivo [53,54].”
BackgroundDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · cited 1×
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
BackgroundDouble nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 1×
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
BackgroundA more efficient method to generate integration-free human iPS cells
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1591 · Cited by 2,061
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608368 · Cited by 1,509
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441 · cited 3×
“Treatment with valproic acid, cyclic tetrapeptide histone deacetylase inhibitors, and thyrotropin-releasing hormone (TRH) analog could enhance SMN protein expression to improve motor neuron defects [50].”
BackgroundMallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Schwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327 · cited 1×
“Since then, other clinical trials have been carried out resulting in clinically measurable visual improvements [76,77].”
BackgroundAllele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251 · cited 4×
“Previous studies using iPSC-derived cardiomyocytes from type-1 LQTS patients revealed that the mutation in KCNQ1 caused potassium ion channel dysfunction resulting in sarcolemmal deficiency [5,6].”
BackgroundResultInfluentialFOXG1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders
Mariani, J., Coppola, G., Zhang, P., Abyzov, A., Provini, L., Tomasini, L., Amenduni, M., Szekely, A., Palejev, D., Wilson, M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.034 · Cited by 1,149 · cited 1×
“Transcriptome and gene network analysis revealed that ASD organoids display a decreased cell cycle, synaptic overgrowth, and overproduction of GABAergic neurons [46].”
BackgroundModelling the long QT syndrome with induced pluripotent stem cells
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., et al. (2011) · Nature · doi:10.1038/nature09747 · Cited by 1,049
Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing
Tsai, S. Q., Wyvekens, N., Khayter, C., Foden, J. A., Thapar, V., Reyon, D., Goodwin, M. J., Aryee, M. J., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2908 · Cited by 952
Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts
Shiba, Y., Gomibuchi, T., Seto, T., Wada, Y., Ichimura, H., Tanaka, Y., Ogasawara, T., Okada, K., Shiba, N., Sakamoto, K., et al. (2016) · Nature · doi:10.1038/nature19815 · Cited by 840
Guilinger, J. P., Thompson, D. B., & Liu, D. R. (2014) · Nature Biotechnology · doi:10.1038/nbt.2909 · Cited by 836
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741
Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model
Kikuchi, T., Morizane, A., Doi, D., Magotani, H., Onoe, H., Hayashi, T., Mizuma, H., Takara, S., Takahashi, R., Inoue, H., et al. (2017) · Nature · doi:10.1038/nature23664 · Cited by 702
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy
Sun, N., Yazawa, M., Liu, J., Han, L., Sanchez-Freire, V., Abilez, O. J., Navarrete, E. G., Hu, S., Wang, L., Lee, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003552 · Cited by 696
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y.-S., Schaniel, C., Lee, D.-F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., et al. (2010) · Nature · doi:10.1038/nature09005 · Cited by 690 · cited 1×
“The capacity of iPSCs for the scalable production of diverse cell types benefits researchers by reducing obstacles with procedures such as apheresis, which involves separating specific components from the blood and retuning the remaining components to the donor’s circulation, whilst obtaining human cells [3].”
BackgroundGenome-wide detection of DNA double-stranded breaks induced by engineered nucleases
Frock, R. L., Hu, J., Meyers, R. M., Ho, Y.-J., Kii, E., & Alt, F. W. (2015) · Nature Biotechnology · doi:10.1038/nbt.3101 · Cited by 673
Lan, F., Lee, A. S., Liang, P., Sanchez-Freire, V., Nguyen, P. K., Wang, L., Han, L., Yen, M., Wang, Y., Sun, N., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.10.010 · Cited by 667 · cited 3×
“This iPSC-derived model played an important role in understanding the effect of MYH7 mutation [14,15].”
BackgroundRubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649 · cited 1×
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
BackgroundTitin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy
Hinson, J. T., Chopra, A., Nafissi, N., Polacheck, W. J., Benson, C. C., Swist, S., Gorham, J., Yang, L., Schafer, S., Sheng, C. C., et al. (2015) · Science · doi:10.1126/science.aaa5458 · Cited by 638 · cited 1×
“iPSC-derived cardiomyocytes from DCM patients revealed that several different mutations including titin [17], troponin T [18], RBM20 [19], and lamin [20–22] are related to DCM through different molecular mechanisms.”
BackgroundLin, Y., Cradick, T. J., Brown, M. T., Deshmukh, H., Ranjan, P., Sarode, N., Wile, B. M., Vertino, P. M., Stewart, F. J., & Bao, G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku402 · Cited by 634
Vatine, G. D., Barrile, R., Workman, M. J., Sances, S., Barriga, B. K., Rahnama, M., Barthakur, S., Kasendra, M., Lucchesi, C., Kerns, J., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.05.011 · Cited by 632
Lonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f3ef9c · Cited by 624
Common genetic variation drives molecular heterogeneity in human iPSCs
Kilpinen, H., Goncalves, A., Leha, A., Afzal, V., Alasoo, K., Ashford, S., Bala, S., Bensaddek, D., Casale, F. P., Culley, O. J., et al. (2017) · Nature · doi:10.1038/nature22403 · Cited by 586 · cited 1×
“They showed that 5–46% of phenotypic variability in iPSCs is due to normal human genetic variation in both inter- and intraclone variability [71].”
BackgroundTargeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility
Xu, H., Wang, B., Ono, M., Kagita, A., Fujii, K., Sasakawa, N., Ueda, T., Gee, P., Nishikawa, M., Nomura, M., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.02.005 · Cited by 581
The MHC locus and genetic susceptibility to autoimmune and infectious diseases
Matzaraki, V., Kumar, V., Wijmenga, C., & Zhernakova, A. (2017) · Genome biology · doi:10.1186/s13059-017-1207-1 · Cited by 566
Lewis-Israeli, Y. R., Wasserman, A. H., Gabalski, M. A., Volmert, B. D., Ming, Y., Ball, K. A., Yang, W., Zou, J., Ni, G., Pajares, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25329-5 · Cited by 536 · cited 1×
“Self-assembling human cardiac organoids have also been used to show the role of BMP4 and Activin A to improve heart organoid chamber formation and vascularization [60].”
MethodModeling human cortical development in vitro using induced pluripotent stem cells
Mariani, J., Simonini, M. V., Palejev, D., Tomasini, L., Coppola, G., Szekely, A. M., Horvath, T. L., & Vaccarino, F. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202944109 · Cited by 526 · cited 1×
“These 3D “organoids” are often found to have instructive morphogenetic cues resulting in self organization similarly found in vivo [53,54].”
BackgroundCooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J. R., Carrillo-Reid, L., Xie, Z., Osborn, T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003985 · Cited by 508 · cited 2×
“The pharmacological capability of Coenzyme Q10, rapamycin, and LRRK2 kinase inhibitor GW5074 were found in iPSC-derived neural cells from PD patients with LRRK2 and PINK1 mutations [38].”
BackgroundModeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent
Fujimori, K., Ishikawa, M., Otomo, A., Atsuta, N., Nakamura, R., Akiyama, T., Hadano, S., Aoki, M., Saya, H., Sobue, G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0140-5 · Cited by 494 · cited 2×
“Ropinirole was identified as a potential therapeutic candidate in ALS patient iPSC-derived motor neurons with TDP-43 and FUS [44].”
BackgroundParkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus
Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W., et al. (2011) · Nature Communications · doi:10.1038/ncomms1453 · Cited by 486 · cited 1×
“SNCA triplication patient iPSC-derived dopaminergic neurons showed α-synuclein protein over accumulation which was consistent with pathological phenotype in PD patient [35].”
ResultMills, R. J., Titmarsh, D. M., Koenig, X., Parker, B. L., Ryall, J. G., Quaife-Ryan, G. A., Voges, H. K., Hodson, M. P., Ferguson, C., Drowley, L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707316114 · Cited by 478 · cited 1×
“They screened over >10,000 organoids to identify optimal maturation conditions with the aim for them to be used in future high-throughput drug screening studies [61].”
BackgroundEfficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9
Mandal, P. K., Ferreira, L. M. R., Collins, R., Meissner, T. B., Boutwell, C. L., Friesen, M., Vrbanac, V., Garrison, B. S., Stortchevoi, A., Bryder, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.10.004 · Cited by 475
Themeli, M., Kloss, C. C., Ciriello, G., Fedorov, V. D., Perna, F., Gonen, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2678 · Cited by 473 · cited 2×
“Taking advantage of iPSCs, T cells can also be differentiated and served as a banked source for allogeneic transplantation [86,87], which decreases the cost and could be scaled-up to achieve “off-the-shelf” availability.”
BackgroundThe HLA system: Genetics, immunology, clinical testing, and clinical implications
Choo, S. Y. (2007) · Yonsei Medical Journal · doi:10.3349/ymj.2007.48.1.11 · Cited by 446 · cited 1×
“A previous study has identified over 9000 alleles within the HLA system [91] making it the most polymorphic genetic system in humans [92].”
BackgroundPathways Disrupted in Human ALS Motor Neurons Identified through Genetic Correction of Mutant SOD1
Kiskinis, E., Sandoe, J., Williams, L. A., Boulting, G. L., Moccia, R., Wainger, B. J., Han, S., Peng, T., Thams, S., Mikkilineni, S., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.03.004 · Cited by 441 · cited 1×
“Fused in sarcoma (FUS) [40,41] and superoxide dismutase 1 (SOD-1) [42,43] are also linked to ALS.”
BackgroundTaylor, C. J., Peacock, S., Chaudhry, A. N., Bradley, J. A., & Bolton, E. M. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.07.014 · Cited by 428
Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2584 · Cited by 404 · cited 2×
“Sharma et al., 2017 performed a high-throughput toxicity screen assessing the cardiotoxicity of small molecule tyrosine kinase inhibitors.”
BackgroundDrukker, M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Hornstein, E., Mandelboim, O., Reisner, Y., & Benvenisty, N. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0188 · Cited by 402 · cited 1×
“Although most of the pluripotent stem cells have low HLA expression [93], iPSC derivatives can trigger an immune response.”
BackgroundSong, W. K., Park, K.-M., Kim, H.-J., Lee, J. H., Choi, J., Chong, S. Y., Shim, S. H., Del Priore, L. V., & Lanza, R. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.04.005 · Cited by 393 · cited 1×
“Since then, other clinical trials have been carried out resulting in clinically measurable visual improvements [76,77].”
BackgroundMatsa, E., Rajamohan, D., Dick, E., Young, L., Mellor, I., Staniforth, A., & Denning, C. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr073 · Cited by 389
Guha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P., & Boyd, A. S. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.01.006 · Cited by 368 · cited 1×
“This was confirmed in mice showing that iPSC-derived cell implantation leads to cellular apoptosis and T cell proliferation [94].”
BackgroundDoi, D., Magotani, H., Kikuchi, T., Ikeda, M., Hiramatsu, S., Yoshida, K., Amano, N., Nomura, M., Umekage, M., Morizane, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17165-w · Cited by 350 · cited 3×
“In their preclinical mouse model, they showed behavioral improvement and no tumorgenicity or toxicity of the cells [90].”
BackgroundInfluentialBilican, B., Serio, A., Barmada, S. J., Nishimura, A. L., Sullivan, G. J., Carrasco, M., Phatnani, H. P., Puddifoot, C. A., Story, D., Fletcher, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202922109 · Cited by 328 · cited 1×
“Familial ALS patient iPSC-derived motor neurons with TDP-43 mutation showed decreased voltage-activated Na+ and K+ currents and increased vulnerability [39].”
BackgroundModeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons
Chen, H., Qian, K., Du, Z., Cao, J., Petersen, A., Liu, H., Blackbourn, L. W., Huang, C.-L., Errigo, A., Yin, Y., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.02.004 · Cited by 318 · cited 1×
“Fused in sarcoma (FUS) [40,41] and superoxide dismutase 1 (SOD-1) [42,43] are also linked to ALS.”
BackgroundSelf-citationMills, R. J., Parker, B. L., Quaife-Ryan, G. A., Voges, H. K., Needham, E. J., Bornot, A., Ding, M., Andersson, H., Polla, M., Elliott, D. A., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.03.009 · Cited by 312 · cited 2×
“Another group, which previously developed a high-throughput bioengineered human cardiac organoid platform [59], has generated organoids for the purpose of identifying pro-proliferative compounds, which was followed by validation and functional screening to identify hit compounds with side effects on contractility [56].”
BackgroundSchafer, S. T., Paquola, A. C. M., Stern, S., Gosselin, D., Ku, M., Pena, M., Kuret, T. J. M., Liyanage, M., Mansour, A. A., Jaeger, B. N., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0295-x · Cited by 288 · cited 1×
“They have also contributed greatly to the understanding of many psychiatric disorders such schizophrenia and autism spectrum disorder [63,64].”
BackgroundZhou, T., Tan, L., Cederquist, G. Y., Fan, Y., Hartley, B. J., Mukherjee, S., Tomishima, M., Brennand, K. J., Zhang, Q., Schwartz, R. E., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.06.017 · Cited by 263 · cited 1×
“Zhou et al., 2017 employed high-content screening of hPSC-forebrain organoids to screen >1000 FDA approved drug candidates.”
BackgroundJiang, H., Ren, Y., Yuen, E. Y., Zhong, P., Ghaedi, M., Hu, Z., Azabdaftari, G., Nakaso, K., Yan, Z., & Feng, J. (2012) · Nature Communications · doi:10.1038/ncomms1669 · Cited by 254 · cited 1×
“PD patient iPSCderived dopaminergic neurons harboring Parkin mutation displayed decreased microtubule stability, increased oxidative stress, reduced dopamine uptake, and increased spontaneous dopamine release [36,37].”
BackgroundHLA engineering of human pluripotent stem cells
Riolobos, L., Hirata, R. K., Turtle, C. J., Wang, P.-R., Gornalusse, G. G., Zavajlevski, M., Riddell, S. R., & Russell, D. W. (2013) · Molecular Therapy · doi:10.1038/mt.2013.59 · Cited by 253
Toward the development of a global induced pluripotent stem cell library
Turner, M., Leslie, S., Martin, N. G., Peschanski, M., Rao, M., Taylor, C. J., Trounson, A., Turner, D., Yamanaka, S., & Wilmut, I. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.08.003 · Cited by 245 · cited 2×
“In allogeneic transplantation surgeries, HLA inconsistency between donors and recipients is the one of the main reasons for failure and rejection [91].”
BackgroundMHC matching improves engraftment of iPSC-derived neurons in non-human primates
Morizane, A., Kikuchi, T., Hayashi, T., Mizuma, H., Takara, S., Doi, H., Mawatari, A., Glasser, M. F., Shiina, T., Ishigaki, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00926-5 · Cited by 244
Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer
Hermanson, D. L., Bendzick, L., Pribyl, L., McCullar, V., Vogel, R. I., Miller, J. S., Geller, M. A., & Kaufman, D. S. (2016) · Stem Cells · doi:10.1002/stem.2230 · Cited by 242 · cited 1×
“NK cells can be differentiated from iPSCs and have proven to be equally effective as primary NK cells [84].”
BackgroundModeling non-syndromic autism and the impact of TRPC6 disruption in human neurons
Griesi-Oliveira, K., Acab, A., Gupta, A. R., Sunaga, D. Y., Chailangkarn, T., Nicol, X., Nunez, Y., Walker, M. F., Murdoch, J. D., Sanders, S. J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.141 · Cited by 236
Coll, M., Perea, L., Boon, R., Leite, S. B., Vallverdú, J., Mannaerts, I., Smout, A., El Taghdouini, A., Blaya, D., Rodrigo-Torres, D., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.027 · Cited by 233
Kondo, T., Imamura, K., Funayama, M., Tsukita, K., Miyake, M., Ohta, A., Woltjen, K., Nakagawa, M., Asada, T., Arai, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.109 · Cited by 221
Wang, H., Guo, W., Mitra, J., Hegde, P. M., Vandoorne, T., Eckelmann, B. J., Mitra, S., Tomkinson, A. E., Van Den Bosch, L., & Hegde, M. L. (2018) · Nature Communications · doi:10.1038/s41467-018-06111-6 · Cited by 205 · cited 2×
“Ropinirole was identified as a potential therapeutic candidate in ALS patient iPSC-derived motor neurons with TDP-43 and FUS [44].”
BackgroundEvaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases
Osborn, M. J., Webber, B. R., Knipping, F., Lonetree, C.-L., Tennis, N., DeFeo, A. P., McElroy, A. N., Starker, C. G., Lee, C., Merkel, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.197 · Cited by 201 · cited 1×
“Moreover, these cells have been well established to avoid graft-versus-host disease by deletion of the TCR α chain [88].”
BackgroundZhang, J., Tao, R., Campbell, K. F., Carvalho, J. L., Ruiz, E. C., Kim, G. C., Schmuck, E. G., Raval, A. N., da Rocha, A. M., Herron, T. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09831-5 · Cited by 201
Development of a human cardiac organoid injury model reveals innate regenerative potential
Voges, H. K., Mills, R. J., Elliott, D. A., Parton, R. G., Porrello, E. R., & Hudson, J. E. (2017) · Development · doi:10.1242/dev.143966 · Cited by 196 · cited 1×
“Cardiac organoids have played an important role in understanding cardiac diseases such as arrhythmia and cardiac repair after injury [56,57].”
BackgroundStudy familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells
Han, L., Li, Y., Tchao, J., Kaplan, A. D., Lin, B., Li, Y., Mich-Basso, J., Lis, A., Hassan, N., London, B., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu205 · Cited by 191 · cited 3×
“This iPSC-derived model played an important role in understanding the effect of MYH7 mutation [14,15].”
BackgroundWarren, C. R., O’Sullivan, J. F., Friesen, M., Becker, C. E., Zhang, X., Liu, P., Wakabayashi, Y., Morningstar, J. E., Shi, X., Choi, J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.01.010 · Cited by 191
HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration
Sugita, S., Mandai, M., Hirami, Y., Takagi, S., Maeda, T., Fujihara, M., Matsuzaki, M., Yamamoto, M., Iseki, K., Hayashi, N., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072217 · Cited by 190 · cited 1×
“This was further confirmed in a clinical trial study with five recruited HLA-matched patients who received HLA-matched RPE cells [97].”
ResultWang, B., Iriguchi, S., Waseda, M., Ueda, N., Ueda, T., Xu, H., Minagawa, A., Ishikawa, A., Yano, H., Ishi, T., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00730-z · Cited by 189
Young, J. E., Boulanger-Weill, J., Williams, D. A., Woodruff, G., Buen, F., Revilla, A. C., Herrera, C., Israel, M. A., Yuan, S. H., Edland, S. D., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.02.004 · Cited by 188 · cited 1×
“IPSC-derived neurons display many of the cellular phenotypes found in AD patients which are associated with amyloid precursor protein (APP) [29], presenilin [30], or SORL1 mutation [31], which are involved in amyloid precursor protein processing; dysfunction of these proteins could”
BackgroundCaspi, O., Huber, I., Gepstein, A., Arbel, G., Maizels, L., Boulos, M., & Gepstein, L. (2013) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000188 · Cited by 186 · cited 2×
“Tumorous cell lines, although able to proliferate, are often incorporated with unwanted genetic or chromosomal abnormalities, which might induce interference to the resulting outcomes [4,5].”
BackgroundNeuronal defects in a human cellular model of 22q11.2 deletion syndrome
Khan, T. A., Revah, O., Gordon, A., Yoon, S.-J., Krawisz, A. K., Goold, C., Sun, Y., Kim, C. H., Tian, Y., Li, M.-Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1043-9 · Cited by 186 · cited 1×
“2 deletion syndrome providing further justification for the use of iPSC-derived organoids as a relevant model for disease modeling [65].”
BackgroundAPP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons.
Moore, S., Evans, L. D. B., Andersson, T., Portelius, E., Smith, J., Dias, T. B., Saurat, N., McGlade, A., Kirwan, P., Blennow, K., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.068 · Cited by 179 · cited 2×
“IPSC-derived neurons display many of the cellular phenotypes found in AD patients which are associated with amyloid precursor protein (APP) [29], presenilin [30], or SORL1 mutation [31], which are involved in amyloid precursor protein processing; dysfunction of these proteins could lead to impaired γ-secretase activit…”
BackgroundNew cell sources for T cell engineering and adoptive immunotherapy
Themeli, M., Rivière, I., & Sadelain, M. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.03.011 · Cited by 179 · cited 2×
“Taking advantage of iPSCs, T cells can also be differentiated and served as a banked source for allogeneic transplantation [86,87], which decreases the cost and could be scaled-up to achieve “off-the-shelf” availability.”
BackgroundStachowiak, E. K., Benson, C. A., Narla, S. T., Dimitri, A., Chuye, L. E. B., Dhiman, S., Harikrishnan, K., Elahi, S., Freedman, D., Brennand, K. J., et al. (2017) · Translational Psychiatry · doi:10.1038/s41398-017-0054-x · Cited by 179 · cited 3×
“They have also contributed greatly to the understanding of many psychiatric disorders such schizophrenia and autism spectrum disorder [63,64].”
BackgroundDisease characterization using LQTS-specific induced pluripotent stem cells
Egashira, T., Yuasa, S., Suzuki, T., Aizawa, Y., Yamakawa, H., Matsuhashi, T., Ohno, Y., Tohyama, S., Okata, S., Seki, T., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs206 · Cited by 178 · cited 2×
“Previous studies using iPSC-derived cardiomyocytes from type-1 LQTS patients revealed that the mutation in KCNQ1 caused potassium ion channel dysfunction resulting in sarcolemmal deficiency [5,6].”
ResultYoshida, S., Miyagawa, S., Fukushima, S., Kawamura, T., Kashiyama, N., Ohashi, F., Toyofuku, T., Toda, K., & Sawa, Y. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.012 · Cited by 178 · cited 1×
“The co-culture models of cardiomyocytes and mesenchymal stem cells have also been shown to improve cardiomyocyte functionality as mesenchymal stem cells secrete soluble growth factors, enhancing cardiomyocyte maturity [25].”
BackgroundWoodruff, G., Young, J. E., Martinez, F. J., Buen, F., Gore, A., Kinaga, J., Li, Z., Yuan, S. H., Zhang, K., & Goldstein, L. S. B. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.018 · Cited by 177
SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons
Zaslavsky, K., Zhang, W.-B., McCready, F. P., Rodrigues, D. C., Deneault, E., Loo, C., Zhao, M., Ross, P. J., El Hajjar, J., Romm, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0365-8 · Cited by 174
Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration
(2017) · New England Journal of Medicine · doi:10.1056/nejmc1706274 · Cited by 171 · cited 1×
“This patient did not experience any complications during surgery or after the surgery, however, the patient was required to wait over 10 months for the surgery and it cost nearly USD 1 million [75].”
BackgroundNakajima, F., Tokunaga, K., & Nakatsuji, N. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0566 · Cited by 168
Matsa, E., Burridge, P. W., Yu, K.-H., Ahrens, J. H., Termglinchan, V., Wu, H., Liu, C., Shukla, P., Sayed, N., Churko, J. M., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.07.006 · Cited by 164 · cited 1×
“Matsa et al., 2016, suggest in their research that iPSC-derived cardiomyocytes retain the inter- and intravariation between and within cell lines.”
ResultSugita, S., Iwasaki, Y., Makabe, K., Kamao, H., Mandai, M., Shiina, T., Ogasawara, K., Hirami, Y., Kurimoto, Y., & Takahashi, M. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.010 · Cited by 156 · cited 1×
“showed that transplantation of RPE cells caused minimal immune reactivity in MHC, the monkey HLA equivalent, matched monkeys [96].”
ResultHoang, P., Wang, J., Conklin, B. R., Healy, K. E., & Ma, Z. (2018) · Nature Protocols · doi:10.1038/nprot.2018.006 · Cited by 156 · cited 1×
“One group has generated a highly complex cardiac organoid that includes a central, void chamber [58].”
BackgroundKawamura, T., Miyagawa, S., Fukushima, S., Maeda, A., Kashiyama, N., Kawamura, A., Miki, K., Okita, K., Yoshida, Y., Shiina, T., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.01.012 · Cited by 145
Siu, C.-W., Lee, Y.-K., Ho, J. C.-Y., Lai, W.-H., Chan, Y.-C., Ng, K.-M., Wong, L.-Y., Au, K.-W., Lau, Y.-M., Zhang, J., et al. (2012) · Aging · doi:10.18632/aging.100503 · Cited by 141 · cited 1×
“found MEK1/2 inhibitors, U0126 and selumetinib (AZD6244) that attenuate proapoptotic phenotype of DCM iPSC-CMs with lamin mutation [20].”
BackgroundSelf-citationSalvarani, N., Crasto, S., Miragoli, M., Bertero, A., Paulis, M., Kunderfranco, P., Serio, S., Forni, A., Lucarelli, C., Ferro, M. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09929-w · Cited by 127
Zhang, H., Xue, C., Shah, R., Bermingham, K., Hinkle, C. C., Li, W., Rodrigues, A., Tabita-Martinez, J., Millar, J. S., Cuchel, M., et al. (2015) · Circulation Research · doi:10.1161/circresaha.117.305860 · Cited by 126
Overview: An iPS cell stock at CiRA
Umekage, M., Sato, Y., & Takasu, N. (2019) · Inflammation and Regeneration · doi:10.1186/s41232-019-0106-0 · Cited by 122
Jang (2019) · doi:10.1038/s12276-019-0352-x · Cited by 114
Environmental Toxin Screening Using Human-Derived 3D Bioengineered Liver and Cardiac Organoids
Forsythe, S. D., Devarasetty, M., Shupe, T., Bishop, C., Atala, A., Soker, S., & Skardal, A. (2018) · Frontiers in Public Health · doi:10.3389/fpubh.2018.00103 · Cited by 112
Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes
Mehta, A., Sequiera, G. L., Ramachandra, C. J. A., Sudibyo, Y., Chung, Y., Sheng, J., Wong, K. Y., Tan, T. H., Wong, P., Liew, R., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu060 · Cited by 110
Parkin mutations reduce the complexity of neuronal processes in iPSC-derived human neurons
Ren, Y., Jiang, H., Hu, Z., Fan, K., Wang, J., Janoschka, S., Wang, X., Ge, S., & Feng, J. (2015) · Stem Cells · doi:10.1002/stem.1854 · Cited by 109 · cited 1×
“PD patient iPSCderived dopaminergic neurons harboring Parkin mutation displayed decreased microtubule stability, increased oxidative stress, reduced dopamine uptake, and increased spontaneous dopamine release [36,37].”
BackgroundLi, S., Pan, H., Tan, C., Sun, Y., Song, Y., Zhang, X., Yang, W., Wang, X., Li, D., Dai, Y., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.013 · Cited by 106 · cited 1×
“Even though rigorous testing is undertaken during the development stages, 90% of drugs fail clinical trials [2].”
BackgroundBassil, R., Shields, K., Granger, K., Zein, I., Ng, S., & Chih, B. (2021) · Nature Communications · doi:10.1038/s41467-021-25344-6 · Cited by 106 · cited 2×
“The screening capability was examined by validating nine compounds, and the authors have successfully demonstrated a protecting effect on neurons with compounds known to inhibit Tau phosphorylation [34].”
BackgroundYoshida, M., Kitaoka, S., Egawa, N., Yamane, M., Ikeda, R., Tsukita, K., Amano, N., Watanabe, A., Morimoto, M., Takahashi, J., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.02.010 · Cited by 102 · cited 1×
“Treatment with valproic acid, cyclic tetrapeptide histone deacetylase inhibitors, and thyrotropin-releasing hormone (TRH) analog could enhance SMN protein expression to improve motor neuron defects [50].”
BackgroundLee, S., Huh, J. Y., Turner, D. M., Lee, S., Robinson, J., Stein, J. E., Shim, S. H., Hong, C. P., Kang, M. S., Nakagawa, M., et al. (2018) · Stem Cells · doi:10.1002/stem.2865 · Cited by 99
Lee, D. S., Chen, J.-H., Lundy, D. J., Liu, C.-H., Hwang, S.-M., Pabon, L., Shieh, R.-C., Chen, C.-C., Wu, S.-N., Yan, Y.-T., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.042 · Cited by 91
Self-citationDe Santis, R., Santini, L., Colantoni, A., Peruzzi, G., de Turris, V., Alfano, V., Bozzoni, I., & Rosa, A. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.09.004 · Cited by 91
Guan, X., Xu, W., Zhang, H., Wang, Q., Yu, J., Zhang, R., Chen, Y., Xia, Y., Wang, J., & Wang, D. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01602-0 · Cited by 91 · cited 1×
“Although there are no efficacy data from their Phase 1/2 clinical trial at the moment, their preclinical study using rat models suggested that the implanted human cardiomyocytes improved heart function through cardiac remodeling [79].”
BackgroundJapanese woman is first recipient of next-generation stem cells
Cyranoski, D. (2014) · Nature · doi:10.1038/nature.2014.15915 · Cited by 89 · cited 1×
“The first in-human clinical trial of iPSC-based cell therapy used an iPSC-derived retinal pigment epithelium (RPE) sheet that was implanted into a Japanese woman with age-related macular degeneration (AMD) in 2014 [73,74].”
Parrotta, E. I., Lucchino, V., Scaramuzzino, L., Scalise, S., & Cuda, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124354 · Cited by 88
Kaufmann, M., Schuffenhauer, A., Fruh, I., Klein, J., Thiemeyer, A., Rigo, P., Gomez-Mancilla, B., Heidinger-Millot, V., Bouwmeester, T., Schopfer, U., et al. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115588287 · Cited by 87 · cited 2×
“Kaufmann et al., 2015, set out to find a therapeutic option for the treatment of fragile X syndrome.”
BackgroundGenome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Shankar, K., Capitini, C. M., & Saha, K. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01741-4 · Cited by 85 · cited 1×
“Moreover, antigen priming is not required for NK cells, therefore, it is not necessary to transplant with HLA matched NK cells [85].”
BackgroundIchise, H., Nagano, S., Maeda, T., Miyazaki, M., Miyazaki, Y., Kojima, H., Yawata, N., Yawata, M., Tanaka, H., Saji, H., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.07.020 · Cited by 80
Jang, Y., Choi, J., Park, N., Kang, J., Kim, M., Kim, Y., & Ju, J. H. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0190-2 · Cited by 77
ERRγ enhances cardiac maturation with T-tubule formation in human iPSC-derived cardiomyocytes
Miki, K., Deguchi, K., Nakanishi-Koakutsu, M., Lucena-Cacace, A., Kondo, S., Fujiwara, Y., Hatani, T., Sasaki, M., Naka, Y., Okubo, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23816-3 · Cited by 76 · cited 3×
“, 2021 identified two compounds, ERRγ agonist and SKP2 inhibitor, that play a role in enhancing CM maturation [24].”
BackgroundInfluentialModeling of LMNA-Related Dilated Cardiomyopathy Using Human Induced Pluripotent Stem Cells
Shah, D., Virtanen, L., Prajapati, C., Kiamehr, M., Gullmets, J., West, G., Kreutzer, J., Pekkanen-Mattila, M., Heliö, T., Kallio, P., et al. (2019) · Cells · doi:10.3390/cells8060594 · Cited by 69
iPSC Modeling of RBM20-Deficient DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy
Briganti, F., Sun, H., Wei, W., Wu, J., Zhu, C., Liss, M., Karakikes, I., Rego, S., Cipriano, A., Snyder, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108117 · Cited by 68 · cited 3×
“iPSC-derived cardiomyocytes from DCM patients revealed that several different mutations including titin [17], troponin T [18], RBM20 [19], and lamin [20–22] are related to DCM through different molecular mechanisms.”
BackgroundHo, R., Workman, M. J., Mathkar, P., Wu, K., Kim, K. J., O’Rourke, J. G., Kellogg, M., Montel, V., Banuelos, M. G., Arogundade, O. A., et al. (2021) · Cell Systems · doi:10.1016/j.cels.2020.10.010 · Cited by 62 · cited 1×
“Recently, a comparison of sporadic and familial ALS iPSC-derived motor neurons revealed that ELAVL3 misexpression in motor neurons becomes a new ALS hallmark in ALS therapeutic drug discovery [45].”
BackgroundTitmarsh, D. M., Glass, N. R., Mills, R. J., Hidalgo, A., Wolvetang, E. J., Porrello, E. R., Hudson, J. E., & Cooper-White, J. J. (2016) · Scientific Reports · doi:10.1038/srep24637 · Cited by 59 · cited 1×
“Another group, which previously developed a high-throughput bioengineered human cardiac organoid platform [59], has generated organoids for the purpose of identifying pro-proliferative compounds, which was followed by validation and functional screening to identify hit compounds with side effects on contractility [56].”
BackgroundBuilding a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
Perales, M.-A., Kebriaei, P., Kean, L. S., & Sadelain, M. (2018) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2017.10.017 · Cited by 59 · cited 1×
“However, the survival rate in patients is a concern [89] and it is necessary to test the safety and efficacy clinically.”
BackgroundPappas, D. J., Gourraud, P.-A., Le Gall, C., Laurent, J., Trounson, A., DeWitt, N., & Talib, S. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0052 · Cited by 57
An eye to the future: Researchers debate best path for stem cell-derived therapies
Chakradhar, S. (2016) · Nature Medicine · doi:10.1038/nm0216-116 · Cited by 56 · cited 1×
“The first in-human clinical trial of iPSC-based cell therapy used an iPSC-derived retinal pigment epithelium (RPE) sheet that was implanted into a Japanese woman with age-related macular degeneration (AMD) in 2014 [73,74].”
Long QT Syndrome Modelling with Cardiomyocytes Derived from Human-induced Pluripotent Stem Cells
Sala, L., Gnecchi, M., & Schwartz, P. J. (2019) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2019.1.1 · Cited by 54
McKeithan, W. L., Feyen, D. A. M., Bruyneel, A. A. N., Okolotowicz, K. J., Ryan, D. A., Sampson, K. J., Potet, F., Savchenko, A., Gómez-Galeno, J., Vu, M., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.08.003 · Cited by 50 · cited 3×
“They also showed that mexiletine can inhibit INa and shorten the QT interval pathological effect of the mutated sodium channel [12].”
BackgroundJosowitz, R., Mulero-Navarro, S., Rodriguez, N. A., Falce, C., Cohen, N., Ullian, E. M., Weiss, L. A., Rauen, K. A., Sobie, E. A., & Gelb, B. D. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.07.018 · Cited by 45
Hong, L., Zhang, M., Ly, O. T., Chen, H., Sridhar, A., Lambers, E., Chalazan, B., Youn, S.-W., Maienschein-Cline, M., Feferman, L., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.04.019 · Cited by 44
Zhang, H., Xue, Y., Pan, T., Zhu, X., Chong, H., Xu, C., Fan, F., Cao, H., Zhang, B., Pan, J., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056264 · Cited by 44
Lam, C. K., Tian, L., Belbachir, N., Wnorowski, A., Shrestha, R., Ma, N., Kitani, T., Rhee, J.-W., & Wu, J. C. (2019) · Circulation Research · doi:10.1161/circresaha.118.314202 · Cited by 39 · cited 1×
“Results showed that verapamil has the strongest inhibition on iPSC-derived cardiomyocyte contractile function and decreased expression of contraction-related genes, such as MYH and troponin I [16].”
BackgroundÁlvarez-Palomo, B., García-Martinez, I., Gayoso, J., Raya, A., Veiga, A., Abad, M. L., Eiras, A., Guzmán-Fulgencio, M., Luis-Hidalgo, M., Eguizabal, C., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02301-0 · Cited by 37
Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons
Huang, C. Y., Nicholson, M. W., Wang, J. Y., Ting, C. Y., Tsai, M. H., Cheng, Y. C., Liu, C. L., Chan, D. Z. H., Lee, Y. C., Hsu, C. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110643 · Cited by 36 · cited 1×
“In a recent study, Huang et al., 2022, have reported the generation of an HLA-homozygous iPSC bank by screening 1000 healthy donors in Taiwan, and established the first drug screening model representing the Han Chinese population in Taiwan [105].”
BackgroundSelf-citationOhuchi, K., Funato, M., Kato, Z., Seki, J., Kawase, C., Tamai, Y., Ono, Y., Nagahara, Y., Noda, Y., Kameyama, T., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0059 · Cited by 34 · cited 8×
“SMA iPSC-derived neurons are not only used in the pathogenic investigation but also in therapeutic discovery.”
MethodInfluentialDesign of efficacious somatic cell genome editing strategies for recessive and polygenic diseases
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20065-8 · Cited by 32 · cited 2×
“Such disease models could also be used in combination with in silico approaches for high-throughput drug discovery and drug development studies [72].”
BackgroundMethodShah, D., Prajapati, C., Penttinen, K., Cherian, R. M., Koivumäki, J. T., Alexanova, A., Hyttinen, J., & Aalto-Setälä, K. (2020) · Cells · doi:10.3390/cells9051153 · Cited by 31
Making it personal: The prospects for autologous pluripotent stem cell-derived therapies
Blair, N. F., & Barker, R. A. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0057 · Cited by 22 · cited 1×
“More recently, iPSC-based cell therapies are switching from autologous transplantation to allogeneic transplantation [81].”
BackgroundAntiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes
Cashman, J. R., Ryan, D., McKeithan, W. L., Okolotowicz, K., Gomez-Galeno, J., Johnson, M., Sampson, K. J., Kass, R. S., Pezhouman, A., Karagueuzian, H. S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01545 · Cited by 11 · cited 5×
“Using iPSC-derived cardiomyocytes from type-3 LQTS patients with SCN5A mutation revealed abnormal calcium transients with dimin- ished INa current density [11].”
BackgroundInfluential
Cited by
Wang, L., Wang, B., Wu, C., Wang, J., & Sun, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031819 · Cited by 237
“2 Duplication ↓spontaneous neuronal activity and calcium signalling; ↓expression of miR-1290 [53]”
BackgroundExploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Chehelgerdi, M., Behdarvand Dehkordi, F., Chehelgerdi, M., Kabiri, H., Salehian-Dehkordi, H., Abdolvand, M., Salmanizadeh, S., Rashidi, M., Niazmand, A., Ahmadi, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01873-0 · Cited by 175
Revolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems
Silva-Pedrosa, R., Salgado, A. J., & Ferreira, P. E. (2023) · Cells · doi:10.3390/cells12060930 · Cited by 84
“This can greatly accelerate the drug development process and ultimately lead to new treatments for patients [46,47].”
BackgroundProgress in Organ Bioprinting for Regenerative Medicine
Wang, X. S., Zhang, D., Singh, Y. P., Yeo, M., Deng, G., Lai, J., Chen, F., Ozbolat, I. T., & Yu, Y. (2024) · Engineering · doi:10.1016/j.eng.2024.04.023 · Cited by 70
“Recent studies have differentiated iPSCs into cells of various lineages such as CMs, neurons, hepatic cells, and ECs [85,86], The field of bioprinting has witnessed a trend of utilizing iPSC-derived cells, such as for the fabrication of cardiac [87], hepatic [43], and pancreatic [88] tissues.”
A Review of Advanced Biomaterials and Cells for the Production of Bone Organoid
Li, C., Zhang, Y., Du, Y., Hou, Z., Zhang, Y., Cui, W., & Chen, W. (2023) · Small Science · doi:10.1002/smsc.202300027 · Cited by 34
Metadata
- Authors
- Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H.
- Affiliations
- Institute of Biomedical Sciences, Academia Sinica (TW)
- Corresponding author
- Hsieh, Patrick C. H.
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-06-06
- Volume
- 11
- Issue
- 11
- Pages
- 1853
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9180434
- OpenAlex
- W4281701292
- Cited by
- 65
- References
- 132
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 15 · 2023: 17 · 2022: 2
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- induced pluripotent stem cells, iPSC-derived cardiomyocytes, iPSC-derived neurons, disease modeling, drug development, cell therapy, regenerative medicine
- MeSH terms
- Drug Development, Animals, Pluripotent Stem Cells, Regenerative Medicine, Induced Pluripotent Stem Cells, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
